Marleen Kok, Group Leader (Associate professor) at The Netherlands Cancer Institute, sharef a post on LinkedIn:
“For an update on the rapidly evolving landscape of neoadjuvant immunotherapy in different cancer types, read our review. It was such a pleasure to write it with a stellar team: ESMO fellow Gil Awada and my amazing colleagues Michiel van der Heijden, Prof Dr Christian Blank, Myriam Chalabi, Tina Cascone.”
Title: The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Authors: Gil Awada, Tina Cascone, Michiel S. van der Heijden, Christian U. Blank, Marleen Kok, Myriam Chalabi
Read the Full Article.
